Capital World Investors rotates from AI froth into drugs, defense and hard assets

The biggest buys table reads like a shopping list for durable growth that isn’t priced like peak AI. They are doubling down on dominant data and distribution platforms, while building a more robust healthcare and energy spine.

• Alphabet (GOOGL, GOOG): Massive adds in both share classes (GOOG up 55.2%, GOOGL up 21.3%) show they want more of the AI upside via search, cloud and YouTube, at a far lower multiple than the GPU suppliers. With value now above $31.6B combined, Alphabet is the clear non‑chip AI core.
• Amazon: A 49.3% share increase and a position now at $10.5B signals conviction that AWS plus logistics leverage are underappreciated. They are explicitly rotating AI enthusiasm into the e‑commerce and cloud toll‑booth.
• Taiwan Semi: A 20.0% add into TSM lifts the stake to $11.1B. This is a bet on the foundry bottleneck at the heart of every AI roadmap, but at a fraction of the hype premium attached to the US GPU names.
• AstraZeneca (new), Amgen, Eli Lilly, UnitedHealth: A new $5.5B AstraZeneca position, plus large adds to Amgen (+26.8%), Lilly (+3.9%) and UnitedHealth (+23.0%), flesh out a second growth pillar: obesity, oncology and managed care. They are deliberately pairing AI’s data story with a drug and reimbursement story.
• TotalEnergies and EOG: The 651.7% explosion in TotalEnergies and a 27.8% add to EOG take energy to 4.8% of the book. That is a clear statement: in a world of sticky inflation and geopolitical fracture, integrated oils and US shale are still essential cash machines.
• Northrop Grumman and TransDigm: Doubling Northrop (+100.7%) and adding 18.0% to TransDigm shows rising confidence that defense budgets and aerospace content per platform will trend up, not down, over the next cycle.

Layered on top are high‑conviction consumer adds — SBUX, HD, RCL, NFLX — which round out a thesis that real‑world demand and services still have legs even if AI multiples compress.

On the sell side, the pattern is blunt: harvest huge wins around the AI hype cluster and clear space in high‑beta software to fund more diversified growth. They are not abandoning AI, they are pruning the most extended limbs.

• Micron and Broadcom: Micron is the single largest trim by dollars (shares down 27.8%, value reduced by an estimated $5.47B) despite still being up 851.1% versus their average cost. Broadcom, their largest single position at 4.91% of the book, is clipped by 5.7% after an 1,842.0% gain. These are classic risk‑management moves: pull chips off the table in memory and infrastructure winners that have already paid out.
• Microsoft, Nvidia, ASML: Small to mid‑size cuts in Microsoft (-4.2%), Nvidia (-0.4%) and ASML (-3.8%) show they are tamping down gross exposure at the very center of the AI narrative rather than exiting. The core thesis stays intact; the sizing gets more sane.
• Cloudflare, Shopify, GE Aerospace, IBM: The aggressive trims in Cloudflare (-36.5%), Shopify (-29.5%), GE Aerospace (-27.7%) and IBM (-22.5%) are more telling. Cloudflare and Shopify are high‑multiple, sentiment‑driven software/commerce names; GE Aerospace is a big winner that can fund higher‑conviction defense and industrial plays; IBM, sitting slightly below cost, is an obvious source of capital. This is a culling of the periphery to reinforce the center.
• Money‑center banks: Cuts to JPMorgan (-15.0%) and Citigroup (-12.8%) while marginally adding to Bank of America (+2.1%) look like a controlled de‑risking of rate‑sensitive financials, not a sector abandonment.

The through‑line: use liquidity in crowded winners and lower‑conviction tech/financials to scale into cheaper, more structurally advantaged compounders elsewhere in the book.

The sector bar chart makes the pivot explicit. Technology is still nearly half the equity exposure at 43.73%, but it’s down from an estimated 48.0% as capital migrates into healthcare, consumer and hard assets.

Health care jumps to 17.06% from 15.99%, powered by the AstraZeneca entry and larger stakes in Amgen, Lilly, Vertex, UnitedHealth and Philip Morris. This isn’t just “defensive healthcare”; it’s a curated mix of GLP‑1s, oncology, specialty biotech and global nicotine — long‑duration cash flows less tied to the economic cycle.

Consumer discretionary rises to 10.03% from 8.83%, driven by Amazon, Netflix, Starbucks, Royal Caribbean, Home Depot and D.R. Horton. They are clearly leaning into normalized travel, services and housing demand rather than speculative consumer tech.

Energy climbs to 4.8% from 3.85%, while utilities edge up to 2.08% and basic materials hold around 2.2% through Wheaton and Agnico. Together with increased defense exposure inside Industrials (now 10.76%), that’s a coherent inflation and geopolitical hedge built from cash‑rich, asset‑backed franchises.

Finance slips to 3.59% from 4.16%, reflecting trims in JPMorgan and Citi. Real estate‑classified payment/e‑commerce plays Visa and MercadoLibre are nudged up, underscoring that they prefer transaction rails and online marketplaces over traditional lenders for financial exposure.

Taken together, this quarter’s moves sketch a manager preparing for a world where AI remains transformative but its equity returns become more dispersed. Capital World Investors is positioning to win if leadership broadens away from a handful of GPU and hyperscale names and back toward platforms, drugs, energy and services.

Expect them to keep trimming around the edges of the AI chip complex when valuations look euphoric, while using any volatility to accumulate in the second‑derivative beneficiaries: Alphabet, Amazon, Taiwan Semi, and high‑quality picks‑and‑shovels like KLA. The core bet is not that AI fades, but that its cash flows will ultimately accrue to cheaper, more diversified franchises.

On the other axis, the build‑out in pharma, defense, energy, utilities and precious metals hints at a base‑case of structurally higher nominal growth and geopolitical tension. In that world, regulated monopolies, drug pipelines and arms makers look like the new bond proxies.

Finally, the willingness to size up in cyclical but dominant consumer names — Starbucks, Home Depot, Royal Caribbean, Netflix — says they are not buying a hard‑landing narrative. They are constructing an all‑weather portfolio: still levered to innovation, but with enough healthcare, cash generative industrials and hard assets that a derating in pure AI doesn’t derail the whole book.